

## Global spotlight 18.2: Key additions for the second half of June 2022



There are four updates to living evidence syntheses that are already included in the public-health measures parts of the COVID-END inventory of ‘best’ evidence syntheses\*, and 28 updates to living evidence syntheses that are already included in the clinical management parts of the inventory.

\*COVID-END assigns ‘best’ status to evidence syntheses based on an assessment of how up-to-date they are (i.e., the date of the last search, with priority given to living reviews), quality (using the AMSTAR tool), and whether there is an evidence profile available (e.g., GRADE).

Taxonomy section	Title	Type of synthesis	Criteria for best evidence synthesis		
			Date of last search	Quality (AMSTAR) rating	Evidence profile (e.g., GRADE) available
Public-health measures	<a href="#">[CanSino] Vaccination with CanSino vaccine slightly reduces the risk of contracting COVID-19, and it may reduce the risk of contracting severe COVID-19; it probably does not increase the risk of serious adverse events</a>	Update to living review	2022-06-16	8/11	Yes
Public-health measures	<a href="#">[Covaxin] Vaccination with Covaxin vaccine reduces the risk of contracting COVID-19 while it may reduce the risk of severe disease; it does not increase the risk of severe adverse events</a>	Update to living review	2022-06-16	6/9	Yes
Public-health measures	<a href="#">[Novavax] Vaccination with Novavax reduces the risk of contracting COVID-19 and it may reduce severe disease, while it does not increase the frequency of severe adverse events</a>	Update to living review	2022-06-16	8/11	Yes
Public-health measures	<a href="#">[BioNTech/Pfizer or Moderna to complete vaccination scheme started with Astra Zeneca against variants of concern] Vaccinating with Astra Zeneca followed by BioNTech/Pfizer or Moderna vaccine may not fully prevent infection (including symptomatic infection) from the Omicron variant of concern</a>	Update to living rapid review	2022-06-22	8/9	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Camostat mesilate] Using camostat to treat hospitalized COVID-19 patients may make little or no difference in mortality, clinical improvement, and disease progression; its safety outcomes are currently uncertain</a>	Update to living review	2022-06-24	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Tocilizumab] Among hospitalized patients, tocilizumab reduces mortality at 28 days and it may also slightly reduce mortality at 60 days; it slightly increases the incidence of clinical improvement, it may make little or no difference in disease progression, and it may slightly increase adverse events</a>	Update to living review	2022-06-24	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[ARGOVIT AgNPs] In people at risk of COVID-19, using ARGOVIT AgNPs may reduce laboratory-confirmed SARS-CoV-2 infections; no data is available for other outcomes</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Bamlanivimab] In people at risk of COVID-19, using bamlanivimab may make little or no difference in laboratory-confirmed SARS-CoV-2 infection and mortality</a>	Update to living review	2022-06-21	10/11	Yes

Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Casirivimab + imdevimab] In people at risk of COVID-19, using casirivimab + imdevimab may reduce suspected, probable and laboratory-confirmed SARS-CoV-2 infections, and it probably does not have an effect on mortality or hospitalization; it probably does not increase adverse events leading to discontinuation of the treatment</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Cilgavimab + tixagevimab] In people at risk of COVID-19, using cilgavimab + tixagevimab may reduce laboratory-confirmed SARS-CoV-2 infections, and it may not have an effect on mortality</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Dimethyl sulfoxide nasal spray] The effects of using dimethyl sulfoxide nasal spray as a prophylactic treatment are currently uncertain</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Hydroxychloroquine + tenofovir disoproxil fumarate/emtricitabine] In people at risk of COVID-19, using hydroxychloroquine + tenofovir disoproxil fumarate/emtricitabine may not have an effect on hospitalization and it may slightly increase adverse events leading to discontinuation of the treatment</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Hydroxychloroquine] Adding prophylactic hydroxychloroquine to standard care does not have an important effect on mortality, hospitalization, and laboratory-confirmed SARS-CoV-2 infection, and it does not increase adverse events leading to discontinuation of the treatment</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Iota-carrageenan] In people at risk of COVID-19, using iota-carrageenan may not have an effect on mortality and it probably does not have an effect on hospitalization; it may also increase adverse events leading to discontinuation of the treatment</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Lopinavir + ritonavir] The effects of using lopinavir + ritonavir as a prophylactic treatment for COVID-19 are currently uncertain</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Melatonin] In people at risk of COVID-19, using melatonin may not have an effect on laboratory-confirmed SARS-CoV-2 infections and hospitalizations, and it probably does not increase adverse events leading to discontinuation of the treatment</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Povidone iodine] In people at risk of COVID-19, using povidone iodine may not have an effect on hospitalizations, and it may slightly increase adverse events leading to discontinuation of the treatment; its effects on other outcomes are uncertain</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Tenofovir disoproxil fumarate/emtricitabine] In people at risk of COVID-19, using tenofovir disoproxil fumarate/emtricitabine probably does not have an effect on hospitalizations, and it may increase adverse events leading to discontinuation</a>	Update to living review	2022-06-21	10/11	Yes

	<a href="#">of the treatment; its effects on other outcomes are uncertain</a>				
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Vitamin C + zinc] In people at risk of COVID-19, using vitamin C + zinc may not have an effect on hospitalizations, and it probably increases adverse events leading to discontinuation of the treatment; its effects on other outcomes are uncertain</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Vitamin C] In people at risk of COVID-19, using vitamin C may not have an effect on hospitalizations, and it may slightly increase adverse events leading to discontinuation of the treatment; its effects on other outcomes are uncertain</a>	Update to living review	2022-06-21	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Colchicine] In hospitalized patients, colchicine probably makes little or no difference in mortality at 28 days and clinical improvement, while it may slightly reduce disease progression and it may increase adverse events; in outpatients, it may make little or no difference in mortality and hospitalization or death, while it probably does not increase serious adverse events</a>	Update to living review	2022-02-28	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Ivermectin] In mild outpatients or hospitalized patients, adding ivermectin to standard care may have no important effect on mortality at 28 days, clinical improvement, and disease progression; in outpatients, it may not increase the risk of serious adverse events and probably does not increase the risk of any adverse event</a>	Update to living review	2022-02-28	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Zilucoplan] The effects of using zilucoplan to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-10	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Clazakizumab] In patients with severe or critical COVID-19, using clazakizumab may reduce mechanical ventilation and it may improve time to symptom resolution; its effects on other outcomes are uncertain</a>	Update to living rapid review	2022-06-08	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Ensitrelvir] The effects of using ensitrelvir to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Ibrutinib] The effects of using ibrutinib to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Interleukin-2] The effects of using interleukin-2 to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Ixezumab] The effects of using ixekizumab to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes

Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Prostacycline] The effects of using prostacycline (including inhaled prostacycline) to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Raloxifene] The effects of using raloxifene to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Reparixin] The effects of using reparixin to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-06-08	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Atovaquone] The effects of using atovaquone to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-03-22	7/11	Yes